Avalo Therapeutics, Inc.AVTX
What Avalo Therapeutics, Inc. does.
We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Our current focus is on completing the Phase 2 (“LOTUS”) trial evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our Phase 3 trial(s).
• Advancing our pipeline through development to regulatory approval—notably and in the near term, by completing our Phase 2 LOTUS trial in HS, preparing to initiate our pivotal trial(s) pending the readout of the Phase 2 LOTUS trial results and considering further indication expansion for abdakibart (AVTX-009);
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Net income | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| Free cash flow | -$40.6M | -$71.0M | -$26.8M | -$30.8M | -$49.1M | — |
More on AVTX.
- Avalo Therapeutics, Inc. summary
- Avalo Therapeutics, Inc. financial statements
- Avalo Therapeutics, Inc. key metrics
- Avalo Therapeutics, Inc. health scores and style box
- Avalo Therapeutics, Inc. earnings
- Avalo Therapeutics, Inc. dividends
- Avalo Therapeutics, Inc. valuation
- Avalo Therapeutics, Inc. ownership and insiders
- Avalo Therapeutics, Inc. peers
Figures from Avalo Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.